Celon Pharma SA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.
Celon Pharma SA (CLN) - Total Assets
Latest total assets as of September 2025: zł471.33 Million PLN
Based on the latest financial reports, Celon Pharma SA (CLN) holds total assets worth zł471.33 Million PLN as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Celon Pharma SA - Total Assets Trend (2012–2024)
This chart illustrates how Celon Pharma SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Celon Pharma SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Celon Pharma SA's total assets of zł471.33 Million consist of 29.5% current assets and 70.5% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 1.5% |
| Accounts Receivable | zł44.01 Million | 8.1% |
| Inventory | zł29.22 Million | 5.4% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł8.15 Million | 1.5% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Celon Pharma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celon Pharma SA's current assets represent 29.5% of total assets in 2024, an increase from 25.2% in 2012.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2024, down from 8.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 8.1% of total assets.
Celon Pharma SA Competitors by Total Assets
Key competitors of Celon Pharma SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Celon Pharma SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Celon Pharma SA generates 0.32x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Celon Pharma SA is currently not profitable relative to its asset base.
Celon Pharma SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 2.67 | 1.69 |
| Quick Ratio | 1.07 | 2.30 | 1.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł28.41 Million | zł 120.99 Million | zł 48.35 Million |
Celon Pharma SA - Advanced Valuation Insights
This section examines the relationship between Celon Pharma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.95 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -4.5% |
| Total Assets | zł543.79 Million |
| Market Capitalization | $120.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Celon Pharma SA's assets below their book value (0.22 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Celon Pharma SA's assets decreased by 4.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Celon Pharma SA (2012–2024)
The table below shows the annual total assets of Celon Pharma SA from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł543.79 Million | -4.48% |
| 2023-12-31 | zł569.31 Million | -6.51% |
| 2022-12-31 | zł608.93 Million | -13.89% |
| 2021-12-31 | zł707.14 Million | +0.50% |
| 2020-12-31 | zł703.64 Million | +18.99% |
| 2019-12-31 | zł591.35 Million | +4.91% |
| 2018-12-31 | zł563.67 Million | +7.36% |
| 2017-12-31 | zł525.05 Million | +13.08% |
| 2016-12-31 | zł464.32 Million | +175.91% |
| 2015-12-31 | zł168.29 Million | +59.61% |
| 2014-12-31 | zł105.44 Million | +27.66% |
| 2013-12-31 | zł82.59 Million | +18.33% |
| 2012-12-31 | zł69.80 Million | -- |